The GISSI-2 trial

Premises, results, epidemiological (and other) implications

C. Fresco, M. G. Franzosi, A. P. Maggioni, G. Tognoni

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Population trials on myocardial infarction have produced significant advances in therapeutic results. The first clearly stated aim of the GISSI-2 protocol was the assessment of the overall benefit to a population attributable to the application of a package of pharmacological treatments (thrombolysis, intravenous beta blockade, and oral aspirin) shown effective in reducing mortality in large-scale randomized clinical epidemiological interest came first: The comparison between drugs was considered a main target of the investigation only within that broader framework, and was explicitly formulated as the direct confrontation between two concepts or two generations of thrombolysis. A selective, highly efficient, and specific new thrombolytic agent, tissue plasminogen activator (tPA), is compared with streptokinase with the expectation that the more selective approach could enhance the benefits of specificity, drastically limiting the systemic risk aspects (hemorrhagic complications). The main results of GISSI-2 are summarized. GISSI-2 may be considered a reliable window on the epidemiology of AMI in a whole country. There are implications for the transfer of these clinical findings into public health applications and for the choice of future research priorities.

Original languageEnglish
Pages (from-to)32-36
Number of pages5
JournalClinical Cardiology
Volume13
Issue number8 SUPPL. 8
Publication statusPublished - 1990

Fingerprint

Streptokinase
Fibrinolytic Agents
Tissue Plasminogen Activator
Population
Aspirin
Epidemiology
Public Health
Myocardial Infarction
Pharmacology
Mortality
Research
Pharmaceutical Preparations
Therapeutics

Keywords

  • acute myocardial infarction
  • epidemiology
  • GISSI-2
  • mortality
  • population trial
  • steptokinase
  • thrombolysis
  • tPA

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Fresco, C., Franzosi, M. G., Maggioni, A. P., & Tognoni, G. (1990). The GISSI-2 trial: Premises, results, epidemiological (and other) implications. Clinical Cardiology, 13(8 SUPPL. 8), 32-36.

The GISSI-2 trial : Premises, results, epidemiological (and other) implications. / Fresco, C.; Franzosi, M. G.; Maggioni, A. P.; Tognoni, G.

In: Clinical Cardiology, Vol. 13, No. 8 SUPPL. 8, 1990, p. 32-36.

Research output: Contribution to journalArticle

Fresco, C, Franzosi, MG, Maggioni, AP & Tognoni, G 1990, 'The GISSI-2 trial: Premises, results, epidemiological (and other) implications', Clinical Cardiology, vol. 13, no. 8 SUPPL. 8, pp. 32-36.
Fresco C, Franzosi MG, Maggioni AP, Tognoni G. The GISSI-2 trial: Premises, results, epidemiological (and other) implications. Clinical Cardiology. 1990;13(8 SUPPL. 8):32-36.
Fresco, C. ; Franzosi, M. G. ; Maggioni, A. P. ; Tognoni, G. / The GISSI-2 trial : Premises, results, epidemiological (and other) implications. In: Clinical Cardiology. 1990 ; Vol. 13, No. 8 SUPPL. 8. pp. 32-36.
@article{2b5ab72835844652909873c71d649883,
title = "The GISSI-2 trial: Premises, results, epidemiological (and other) implications",
abstract = "Population trials on myocardial infarction have produced significant advances in therapeutic results. The first clearly stated aim of the GISSI-2 protocol was the assessment of the overall benefit to a population attributable to the application of a package of pharmacological treatments (thrombolysis, intravenous beta blockade, and oral aspirin) shown effective in reducing mortality in large-scale randomized clinical epidemiological interest came first: The comparison between drugs was considered a main target of the investigation only within that broader framework, and was explicitly formulated as the direct confrontation between two concepts or two generations of thrombolysis. A selective, highly efficient, and specific new thrombolytic agent, tissue plasminogen activator (tPA), is compared with streptokinase with the expectation that the more selective approach could enhance the benefits of specificity, drastically limiting the systemic risk aspects (hemorrhagic complications). The main results of GISSI-2 are summarized. GISSI-2 may be considered a reliable window on the epidemiology of AMI in a whole country. There are implications for the transfer of these clinical findings into public health applications and for the choice of future research priorities.",
keywords = "acute myocardial infarction, epidemiology, GISSI-2, mortality, population trial, steptokinase, thrombolysis, tPA",
author = "C. Fresco and Franzosi, {M. G.} and Maggioni, {A. P.} and G. Tognoni",
year = "1990",
language = "English",
volume = "13",
pages = "32--36",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "8 SUPPL. 8",

}

TY - JOUR

T1 - The GISSI-2 trial

T2 - Premises, results, epidemiological (and other) implications

AU - Fresco, C.

AU - Franzosi, M. G.

AU - Maggioni, A. P.

AU - Tognoni, G.

PY - 1990

Y1 - 1990

N2 - Population trials on myocardial infarction have produced significant advances in therapeutic results. The first clearly stated aim of the GISSI-2 protocol was the assessment of the overall benefit to a population attributable to the application of a package of pharmacological treatments (thrombolysis, intravenous beta blockade, and oral aspirin) shown effective in reducing mortality in large-scale randomized clinical epidemiological interest came first: The comparison between drugs was considered a main target of the investigation only within that broader framework, and was explicitly formulated as the direct confrontation between two concepts or two generations of thrombolysis. A selective, highly efficient, and specific new thrombolytic agent, tissue plasminogen activator (tPA), is compared with streptokinase with the expectation that the more selective approach could enhance the benefits of specificity, drastically limiting the systemic risk aspects (hemorrhagic complications). The main results of GISSI-2 are summarized. GISSI-2 may be considered a reliable window on the epidemiology of AMI in a whole country. There are implications for the transfer of these clinical findings into public health applications and for the choice of future research priorities.

AB - Population trials on myocardial infarction have produced significant advances in therapeutic results. The first clearly stated aim of the GISSI-2 protocol was the assessment of the overall benefit to a population attributable to the application of a package of pharmacological treatments (thrombolysis, intravenous beta blockade, and oral aspirin) shown effective in reducing mortality in large-scale randomized clinical epidemiological interest came first: The comparison between drugs was considered a main target of the investigation only within that broader framework, and was explicitly formulated as the direct confrontation between two concepts or two generations of thrombolysis. A selective, highly efficient, and specific new thrombolytic agent, tissue plasminogen activator (tPA), is compared with streptokinase with the expectation that the more selective approach could enhance the benefits of specificity, drastically limiting the systemic risk aspects (hemorrhagic complications). The main results of GISSI-2 are summarized. GISSI-2 may be considered a reliable window on the epidemiology of AMI in a whole country. There are implications for the transfer of these clinical findings into public health applications and for the choice of future research priorities.

KW - acute myocardial infarction

KW - epidemiology

KW - GISSI-2

KW - mortality

KW - population trial

KW - steptokinase

KW - thrombolysis

KW - tPA

UR - http://www.scopus.com/inward/record.url?scp=0025033902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025033902&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 32

EP - 36

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 8 SUPPL. 8

ER -